Ultragenyx trades pipeline risk for launch risk

Ultragenyx has had a split year. It won two FDA approvals for gene therapies in a month, sold the vouchers that came with them for $413 million, and lost two phase 3 trials in nine months.

The technology

The company develops treatments for rare genetic diseases. Its revenue today comes from products it markets or partners: Crysvita brought in $156 million in the second quarter, Dojolvi $27 million, Evkeeza $21 million and Mepsevii $10 million. The newest assets are AAV gene therapies, one-time infusions that deliver a working copy of a gene. Fayuvi treats Sanfilippo syndrome type A and received standard full approval. Genglycos treats glycogen storage disease type Ia and received accelerated approval, which means the FDA wants two years of commercial data on 50 patients and 20 controls.

The company also uses antisense drugs, which silence or modulate gene expression. That approach produced apazunersen, which failed in Angelman syndrome.

The odds

The two approvals are done, so the odds now apply to what is left. The BIO/Informa/QLS study of 2011-2020 programs puts the chance of moving from phase 3 to a filing at 57.8% overall and 60.4% in rare disease. Filing to approval runs 90.6% overall and 93.6% in rare disease. From phase 1, the study found rare disease programs reach approval 17.0% of the time, against 7.9% across all programs.

Ultragenyx's recent record shows how wide the spread is. Phase 3 trials of setrusumab in brittle bone disease missed their fracture endpoints in December, and Aspire missed in September. Its two gene therapies, by contrast, cleared the FDA after a manufacturing rejection on one and an accelerated route on the other. The next test cases are UX701 for Wilson disease, with dose-finding data expected in the fourth quarter, and DTX301 for OTC deficiency, where a second phase 3 endpoint is due in the first half of 2027, per the second-quarter release.

The money

Cash, equivalents and marketable securities were $436 million on June 30, after $97 million of operating cash use in the quarter. Revenue that quarter was a company record $214 million, and 2026 guidance is $730 million to $760 million before any new launches. The company has said it expects profitability in 2027 and a drop of at least 15% in combined R&D and SG&A spending that year.

The voucher sales add to that. The first sale brings $210 million, with 20% owed to the NIH, and the second brings $203 million. Both need antitrust clearance. In February the company cut 10% of its workforce with a restructuring charge estimated at about $50 million, and after the Angelman failure it said it would define further expense reductions.

The risks

Launch execution is the first. Fayuvi lists at $3.95 million and Genglycos at $2.7 million, per Bioxconomy, and both depend on payers and treatment centers that have little track record with such products. The accelerated approval of Genglycos also leaves the label tied to follow-up data.

The second is the cost base. The company spent $167 million on research in the second quarter, and the Angelman result thins the late-stage pipeline. Aurora, the open-label Angelman study, is still enrolling. Third is generic exposure: Dojolvi now has two settlements set for January 2033, but other cases are open.

Our read

Ultragenyx has turned a pipeline into products, which is what the story needed, and it has cash from vouchers that reduces near-term financing pressure. What it does not yet have is revenue from the new launches or a late-stage program to follow Aspire. The next year will show whether Crysvita, Dojolvi and two gene therapies can carry a leaner company to the profit target. The first evidence will be launch numbers and the size of the expense cuts, neither of which has a date.